Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory.

IF 2.8 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Therapeutic Drug Monitoring Pub Date : 2024-04-09 DOI:10.1097/ftd.0000000000001200

Paula Elizabeth Keating, Barry D Hock, Paul K L Chin, John Liston O'Donnell, Murray Lindsay Barclay

引用次数: 0

Abstract

Detecting antidrug antibodies (ADAs) against infliximab or adalimumab is useful for therapeutic drug monitoring. Various ADA detection methods exist, and antibody titer is an output in some algorithms. Homogenous mobility shift assay (HMSA) measures relative ADA concentration and determines drug-ADA complex size in vitro. However, the relevance of complex size determination in drug monitoring remains unclear. Hence, the association between complex size, ADA concentration, and sample detectable neutralizing activity was evaluated.

查看原文本刊更多论文

评估在临床实验室中检测英夫利西单抗和阿达木单抗抗药抗体的均质迁移试验

检测针对英夫利昔单抗或阿达木单抗的抗药抗体（ADA）有助于治疗药物监测。目前有多种 ADA 检测方法，抗体滴度是某些算法的输出结果。均相迁移率测定法（HMSA）可在体外测量 ADA 的相对浓度并确定药物-ADA 复合物的大小。然而，复合物大小测定与药物监测的相关性仍不明确。因此，我们对复合物大小、ADA 浓度和样本检测到的中和活性之间的关联进行了评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Drug Monitoring 医学-毒理学

CiteScore

5.00

自引率

8.00%

发文量

213

审稿时长

4-8 weeks

期刊介绍： Therapeutic Drug Monitoring is a peer-reviewed, multidisciplinary journal directed to an audience of pharmacologists, clinical chemists, laboratorians, pharmacists, drug researchers and toxicologists. It fosters the exchange of knowledge among the various disciplines–clinical pharmacology, pathology, toxicology, analytical chemistry–that share a common interest in Therapeutic Drug Monitoring. The journal presents studies detailing the various factors that affect the rate and extent drugs are absorbed, metabolized, and excreted. Regular features include review articles on specific classes of drugs, original articles, case reports, technical notes, and continuing education articles.